- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02544945
Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall Radiotherapy
Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall Radiotherapy: A Feasibility Study Measuring Bolus Spatial Accuracy, Dosimetric Accuracy and Treatment Set-up Time
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Schema
Intervention
All subjects receive standard chest wall radiotherapy doses as follows:
- Half the days no bolus is applied to the chest wall as per the standard of care
- Half the days bolus is applied - alternating days between standard 5mm rubber bolus and the experimental 3D printed bolus.
Primary and Secondary Outcomes Each subject acts as their own control comparing the standard rubber bolus with the 3D printed bolus in terms of
- The volume of air-gap between the bolus and the chest wall skin
- The time it takes the radiation therapists to set up the patient
- The calculated versus measured dose on the skin
Sample size 16 patients over 4 months
- Background and Rationale
In Canada, 25,000 women are diagnosed with breast cancer each year. Approximately 20% of these women undergo mastectomy (removal of the entire breast) as part of their curative treatment program. Radiotherapy is administered to the chest wall (where the breast was) in women whose breast cancer has spread to the lymph nodes
or in other situations in which there is a high chance there might be microscopic amounts of cancer cells left over on the chest wall. A meta-analysis of 25 randomized trials involving 8505 lymph node positive women showed post-mastectomy radiotherapy improved 10-year chest wall control rates from 73% to 92.5%. The same overview showed 15-year overall survival increased by 5.4% (60.1 vs 54.7%) in those women undergoing radiotherapy compared to those who did not.
Applying radiotherapy evenly to the chest wall during a course of 16-25 daily radiation treatments is technically challenging because, without modification, the high-energy radiotherapy machines under-dose the superficial tissue (exactly where the cancer cells might reside). To compensate for this phenomenon, a flexible polymer (rubber) "bolus" layer 3-10 mm thick is placed on the skin of the chest wall on some or all days of a radiation course. All sorts of bolus are used internationally from rubber to candle wax slabs. This standard 'bolus', typically 40 cm wide by 40 cm long, is placed on the chest wall and kept in place with tape and straps for the 15 minutes it takes to set up and administer the radiotherapy each day the bolus is applied. Because the contour of each women's chest wall is different and often include 'peaks and valleys' in the tissue, there is inevitably some 'air gaps' between the skin and the bolus material. This air gap, as seen easily on set up imaging, varies from day to day because the radiation therapists can't reproduce the exact placement of bolus, and women undergoing treatment can't get back into the exact same position on the radiotherapy bed each day. The varying air gaps can affect how much radiotherapy is getting to the skin, and can produce potential under-dosing of the cancer cells or overdosing of the normal skin.
In the Department of Radiation Oncology in Halifax the investigators have developed an innovative solution to this problem of air gap by using a 3D printing technology to create bolus that will be tailored to the exact shape of a patient's chest wall. The investigators have approximately 3 years of experience in producing 3D printed bolus for radiotherapy applications, including rigorous assessment of spatial and dosimetric accuracy of the tissues underneath the bolus. Previous research focused on medical physics validation studies, producing a 'smart bolus' to tailor electron therapy treatments at multiple treatment sites. Through this work the investigators have demonstrated that printed bolus conforms precisely even to complex patient anatomy, based on realistic phantom studies (i.e., models of patients including challenging situations e.g., treating part of a foot or ear). The bolus is designed directly from the planning CT data the patient anatomy, which is required for each patient for usual treatment planning calculations. The 3D printed bolus is typically 5 mm thick for x-ray photon beam applications and consists of polylactic acid (PLA), which is derived from starches (corn, sugar tapioca), inert, and commonly used for e.g., drinking cups and surgical pins. The average density of 3D bolus is controllable during printing and thus the investigators are able to replicate the density of the standard rubber bolus material. The investigators have shown previously that the material is accurately accounted for by the treatment planning system as confirmed in another study.
A recent in-house study of 3D printed bolus of the thickness used for this study show the calculated and measured on the machine closely correlate.
In the proposed study, producing a 3D printed bolus for each patient's chest wall could produce multiple advantages over the current technique:
- The 3D bolus may decrease the amount of air gap between the bolus and the skin. Air gap currently limits the accuracy and uniformity of delivered radiation therapy. The 3D printed bolus would be individualized for every patient and designed and fabricated with sub-millimeter precision;
- The time required by multiple radiation therapists to prepare the bolus setup prior to CT imaging may be reduced, particularly for challenging anatomies, given that the 3D printed bolus is produced in an automated way from CT data afterwards (without the patient and therapists present).
- The time to set up a patient on the treatment machine (linear accelerator) may be decreased if individualized bolus 'slips' into place (compared to status-quo where bolus positioning can be iterative, error-prone and time-consuming).
- As each patient will have their own individualized bolus, issues of infection control (contamination of bacteria from reusing the standard bolus) will be mitigated.
3. Study Objectives
To test whether 3D printed bolus produces less air gap, is faster to apply, and produces a reliable buildup of radiotherapy compared with standard rubber bolus on women undergoing chest wall radiotherapy.
4. Study Methods
This is a single-centre study accruing breast cancer patients who have already agreed to undergo chest wall radiotherapy
Study Flow for an Individual Patient
- Accrual of patient and completion of consent process
- CT simulation and standard bolus production (done exactly as per current standard of care)
- Production of 3D printed bolus using the Simulation CT scan
- Choice of location and calculation of skin dose
Creation of an individualized patient treatment plan
- Plan generated by dosimetrists - alternating bolus on and bolus off
- Outline of which days will be standard bolus and 3D bolus
- Delivery of Radiotherapy on No bolus days- as per standard of care
Delivery of Radiotherapy on Bolus days
- Application of the Diodes to the Chest wall
- Timing of Set up time
- CBCT scan on machine for set up (allows for measurement of air gap afterwards)
Monitoring of patient while on and after treatment
- Air gap calculation
- Measured dose to the skin
- Skin reaction
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- NSHA-QEII Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women undergoing radiotherapy to the chest wall for the treatment of breast cancer with radical intent.
Exclusion Criteria:
- Patients in whom the Radiation Oncologist plans to either omit bolus for more than half of the treatments (rarely happens).
- Patients undergoing a non-standard chest-wall technique (eg. VMAT)
- Pregnant or plans to get pregnant during radiotherapy
- Inability to obtain informed consent or adhere to the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Standard Bolus
The radiotherapy treatment days when the standard bolus is used
|
A standard 5mm-thick piece of rubber is placed on the patient's chest wall
|
|
EXPERIMENTAL: 3D printed bolus
the radiotherapy treatment days when the 3D bolus is used
|
Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall.
This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy.
The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Air gap under bolus
Time Frame: Up to 3 month
|
Air gap is defined as a) the greatest distance from the skin to the bolus measured perpendicular to the chest wall, and b) the maximal area of skin underlying the maximal air pocket
|
Up to 3 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Set up time
Time Frame: Up to 3 months
|
Measured as the time it takes to lay the patient down on the radiotherapy table to the time it takes to finish placing the bolus.
|
Up to 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert DH Rutledge, MD, Capital Health, Canada
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3DBolus
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Standard bolus
-
Tartu University HospitalEstonian Research CouncilUnknown
-
Yale UniversityCompleted
-
All India Institute of Medical Sciences, New DelhiCompletedRenal Cell Carcinoma | Transitional Cell Carcinoma | AML | Renal CystsIndia
-
Wageningen UniversityRecruiting
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
AC Camargo Cancer CenterCompletedBreast Cancer | RadiodermatitisBrazil
-
Imperial College LondonDexCom, Inc.UnknownType 1 Diabetes MellitusUnited Kingdom
-
University Hospital, Gentofte, CopenhagenCompleted
-
Wageningen UniversityGelderse Vallei HospitalRecruitingMuscle Wasting in Critically IllNetherlands
-
University of VirginiaJuvenile Diabetes Research FoundationCompletedType 1 DiabetesUnited States